Fredrik Hubinette - Klaria Pharma Chairman CTO

KLAR Stock

SEK 0.42 0.03 6.67%

Insider

Fredrik Hubinette is Chairman CTO of Klaria Pharma Holding

Age	54
Phone	46 84 46 42 99
Web	https://www.klaria.com

Klaria Pharma Management Efficiency

The company has return on total asset (ROA) of (0.2915) % which means that it has lost $0.2915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8766) %, meaning that it generated substantial loss on money invested by shareholders. Klaria Pharma's management efficiency ratios could be used to measure how well Klaria Pharma manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Klaria Pharma to Peers

Predict price of Klaria Pharma

Klaria Pharma Holding has accumulated 1.02 M in total debt. Klaria Pharma Holding has a current ratio of 0.67, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Klaria Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Klaria Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Klaria Pharma Holding sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Klaria to invest in growth at high rates of return. When we think about Klaria Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Adnan Deronic	Cantargia AB	N/A
	Martin Norin	Kancera AB	64
	Dominique Tersago	Cantargia AB	61
	Marcuss	Cantargia AB	N/A
	BSc JD	Xintela AB	65
	Thomas Olin	Kancera AB	65
	Hans Richter	Kancera AB	74
	Peter Madsen	Cantargia AB	N/A
	Johanna Christensen	Cantargia AB	N/A
	Niclas Brynne	Kancera AB	62
	Torbjrn Lundstrm	Kancera AB	70
	Peter Selin	Kancera AB	50
	Susanne Lagerlund	Cantargia AB	N/A
	Ignacio GarciaRibas	Cantargia AB	N/A
	Nina Valkama	Cantargia AB	N/A
	Per Norlen	Xintela AB	53
	Kjell Sjstrm	Cantargia AB	N/A
	Thoas MD	Cantargia AB	61

Klaria Pharma Holding AB develops treatment methods in the therapeutic fields of migraine and pain related to cancer worldwide. Klaria Pharma Holding AB was founded in 2014 and is based in Uppsala, Sweden. Klaria Pharma is traded on Stockholm Stock Exchange in Sweden. Klaria Pharma Holding (KLAR) is traded on Stockholm Exchange in Sweden and employs 6 people.

Management Performance

	Return On Equity	-0.88
	Return On Asset	-0.29

Klaria Pharma Holding Leadership Team

Elected by the shareholders, the Klaria Pharma's board of directors comprises two types of representatives: Klaria Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Klaria. The board's role is to monitor Klaria Pharma's management team and ensure that shareholders' interests are well served. Klaria Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Klaria Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Hans MD, Chief Officer
	Hans Richter, Chief Consultative
	Susan Suchdev, Chief Officer
	Fredrik Hubinette, Chairman CTO
	Marc Willuhn, Manufacturing Chemistry
	Scott Boyer, Chief Director
	Jesper Wiklund, Chief Officer

Klaria Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Klaria Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.88
	Return On Asset	-0.29
	Operating Margin	(9.48) %
	Current Valuation	88.14 M
	Shares Outstanding	63.1 M
	Shares Owned By Insiders	10.73 %
	Shares Owned By Institutions	9.75 %
	Price To Earning	(18.43) X
	Price To Book	1.42 X
	Price To Sales	8.00 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Klaria Stock Analysis

When running Klaria Pharma's price analysis, check to measure Klaria Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Klaria Pharma is operating at the current time. Most of Klaria Pharma's value examination focuses on studying past and present price action to predict the probability of Klaria Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Klaria Pharma's price. Additionally, you may evaluate how the addition of Klaria Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC